FBT selects 30 biotechnology stocks based on sales, sales as a percentage of R&D expenditures, and R&D growth compared to three years ago. The ETF launched 19 years ago and has delivered exceptional ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...

Biotech stocks have a way of making smart people do dumb things. It starts innocently enough. You read about a "breakthrough" that sounds like it came straight out of science fiction. A tiny company ...

Trevi Therapeutics shifts to late-stage biotech with Haduvio for IPF chronic cough. Click here to read my latest analysis of ...

Jacob Funds, a mutual fund company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded ...

Mon, August 4, 2025 at 11:15 AM UTC Viking Therapeutics (NASDAQ: VKTX) represents exactly this type of overlooked opportunity, trading at a valuation of just $3.7 billion as of Aug. 1, despite owning ...

The Invesco Biotechnology & Genome ETF (PBE) was launched on June 23, 2005, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of the ...

However, there is one key reason the stock could still deliver outstanding returns over the long run: Its pipeline could help ...

Single-use technologies (SUT) are well-suited for modular production environments and represent a valuable solution in today’s ever-evolving biologics development landscape. Though SUTs have been ...

Viking's dual-pathway GLP-1/GIP approach with both injectable and oral delivery options could differentiate it in the crowded obesity drug market. The company's Phase 2 oral VK2735 readout, expected ...